Stocklytics Platform
Asset logo for symbol PHAT
Phathom Pharmaceuticals
PHAT43
$8.18arrow_drop_up0.74%$0.06
Asset logo for symbol PHAT
PHAT43

$8.18

arrow_drop_up0.74%

Performance History

Chart placeholder
Key Stats
Open$8.08
Prev. Close$8.10
EPS-5.74
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range7.60
8.21
52 Week Range6.06
19.71
Ratios
Revenue-
EBITDA Margin %-
EPS-5.74

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Phathom Pharmaceuticals (PHAT)

Phathom Pharmaceuticals Inc (PHAT) is a leading biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. With a strong emphasis on research and development, the company is dedicated to improving the lives of patients suffering from conditions such as gastroesophageal reflux disease (GERD) and other acid-related disorders. PHAT is committed to advancing innovative therapies that address unmet medical needs and provide patients with improved outcomes.
The stock price history of Phathom Pharmaceuticals Inc (PHAT) reflects the company's significant growth and potential. Over the past few years, the stock has seen a steady increase in value, driven by positive clinical trial results and promising drug development programs. Investors have shown confidence in PHAT's ability to deliver groundbreaking treatments and the stock has responded accordingly. With a strong pipeline of potential therapies, Phathom Pharmaceuticals Inc is well-positioned for future success.
Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Terrie J. Curran
Headquarters
Florham Park
Employees
112
Exchange
NASDAQ
add Phathom Pharmaceuticals  to watchlist

Keep an eye on Phathom Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the market capitalization of Phathom Pharmaceuticals (PHAT)?

Phathom Pharmaceuticals (PHAT) has a market capitalization of $559.33M. The average daily trading volume is 8.05, indicating the stock's liquidity and investor engagement.
help

What is Phathom Pharmaceuticals 's (PHAT) price per share?

The current price per share for Phathom Pharmaceuticals (PHAT) is $8.18. The stock has seen a price change of $0.06 recently, indicating a 0.74% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Phathom Pharmaceuticals (PHAT)?

For Phathom Pharmaceuticals (PHAT), the 52-week high is $19.71, which is 140.95% from the current price. The 52-week low is $6.06, the current price is 34.87% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Phathom Pharmaceuticals (PHAT) a growth stock?

Phathom Pharmaceuticals (PHAT) has shown an average price growth of -5.2% over the past three years. It has received a score of 16 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Phathom Pharmaceuticals as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Phathom Pharmaceuticals (PHAT) stock price performance year to date (YTD)?

As of the latest data, Phathom Pharmaceuticals (PHAT) has a year-to-date price change of -10.8%. Over the past month, the stock has experienced a price change of -8.81%. Over the last three months, the change has been -53.31%. Over the past six months, the figure is -21.35%. Looking at a longer horizon, the five-year price change stands at -75.21%.
help

Is Phathom Pharmaceuticals (PHAT) a profitable company?

Phathom Pharmaceuticals (PHAT) has a net income of -$201.59M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 75.51% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -432.95% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $515K. Operating income is noted at -$167.31M. Furthermore, the EBITDA is -$287.14M.

Take Your Investments to a Whole New Level